Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 9027 results

  1. Botulinum toxin injection to cricopharyngeal muscle for retrograde cricopharyngeal dysfunction (RCPD)

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Parathyroid autofluorescence and parathyroid angiography

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. eXroid for internal haemorrhoids

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Apraglutide for treating short bowel syndrome [ID6533]

    Awaiting development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pegunigalsidase alfa every 4 weeks for treating Fabry disease [TSID12346]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Siponimod for treating multiple sclerosis in people 10 to 17 years [TSID12317]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    In development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development